VKTX - バイキング・セラピュ―ティクス (Viking Therapeutics Inc.)

VKTXのニュース

   Viking Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/09 06:27:14 Kwhen Finance
Viking Therapeutics Inc (VKTX) shares closed today at 0.5% above its 52 week low of $4.18, giving the company a market cap of $328M. The stock is currently down 8.7% year-to-date, down 33.6% over the past 12 months, and up 233.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 26.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 64.5% The company's stock price performance over the past 12 months lags the peer average by 67.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61  2021/12/24 08:18:41 ETF Daily News
Viking Therapeutics, Inc. (NASDAQ:VKTX)s share price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $5.61 and traded as low as $4.86. Viking Therapeutics shares last traded at $5.18, with a volume of 841,181 shares. A number of equities analysts have commented on [] The post Viking Therapeutics (NASDAQ:VKTX) Shares Cross Below 50-Day Moving Average of $5.61 appeared first on ETF Daily News .
   Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $13.93  2021/12/23 23:34:43 Transcript Daily
Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have been given a consensus rating of Buy by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued a report on the stock in []
   Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021?  2021/12/18 13:00:00 Stocks Register
Viking Therapeutics Inc. (NASDAQ:VKTX) shares, rose in value on Friday, 12/17/21, with the stock price up by 5.59% to the previous days close as strong demand from buyers drove the stock to $4.91. Actively observing the price movement in the last trading, the stock closed the session at $4.65, falling within a range of $4.60 Viking Therapeutics Inc. (NASDAQ: VKTX): Whats Next In 2021? Read More »
   Metropolitan Life Insurance Co NY Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)  2021/12/06 09:46:41 Dakota Financial News
Metropolitan Life Insurance Co NY grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 47,695.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,559 shares of the biotechnology companys stock after buying an additional 9,539 shares during the quarter. Metropolitan Life []
   Viking Therapeutics, Inc. (NASDAQ:VKTX) Expected to Post Earnings of -$0.19 Per Share  2021/11/20 15:36:41 Transcript Daily
Equities research analysts forecast that Viking Therapeutics, Inc. (NASDAQ:VKTX) will post ($0.19) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Viking Therapeutics earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.22). Viking Therapeutics reported earnings of ($0.15) per share in the []
   Viking Therapeutics (NASDAQ:VKTX) Now Covered by Analysts at Maxim Group  2021/11/13 17:42:41 Transcript Daily
Maxim Group initiated coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note published on Friday morning, TipRanks reports. The firm issued a buy rating and a $14.00 target price on the biotechnology companys stock. Several other research firms also recently commented on VKTX. Zacks Investment Research upgraded shares of Viking Therapeutics from a []
   Viking Therapeutics (NASDAQ:VKTX) Coverage Initiated by Analysts at Maxim Group  2021/11/13 17:04:41 Dakota Financial News
Maxim Group initiated coverage on shares of Viking Therapeutics (NASDAQ:VKTX) in a research note issued on Friday, TipRanks reports. The firm set a buy rating and a $14.00 price target on the biotechnology companys stock. Maxim Groups price objective indicates a potential upside of 127.64% from the companys current price. VKTX has been the topic []
   Geode Capital Management LLC Purchases 95,701 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)  2021/11/11 09:30:41 Dakota Financial News
Geode Capital Management LLC raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 9.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 1,160,325 shares of the biotechnology companys stock after acquiring an additional 95,701 shares during the period. Geode Capital Management LLCs holdings in Viking Therapeutics were worth $6,950,000 as of []
   Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from BMO Capital Markets  2021/11/11 08:46:43 Transcript Daily
BMO Capital Markets reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report released on Monday morning, Price Targets.com reports. They currently have a $15.00 price target on the biotechnology companys stock. Other equities research analysts also recently issued reports about the stock. Raymond James lifted their price target on shares []
   Viking Therapeutics to Participate in Upcoming Investor Conferences  2021/09/02 20:05:00 PR Newswire
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming
   Viking Therapeutics: Remaining Bullish And Sticking To My Plan  2021/08/27 15:52:04 Seeking Alpha
   Viking Therapeutics (VKTX) Investor Presentation - Slideshow  2021/08/13 19:36:01 Seeking Alpha
   Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q2 2021 Results - Earnings Call Transcript  2021/07/29 01:27:09 Seeking Alpha
   Viking Therapeutics shares fall after wider Q2 net loss  2021/07/28 21:00:06 Seeking Alpha

calendar